Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents)
  4. Volume 24, Issue 18
  5. Article
Volume 24, Issue 18
  • ISSN: 1871-5206
  • E-ISSN:

Abstract

Objective

This investigation aims to explore the expression levels of serine protease 8 (PRSS8) in gefitinib-resistant Non-Small Cell Lung Cancer (NSCLC) cell lines (PC9/GR) and elucidate its mechanism of action.

Methods

We measured PRSS8 expression in gefitinib-resistant (PC9/GR) and sensitive (PC9) NSCLC cell lines using Western blot analysis. PRSS8-specific small interfering RNA (PRSS8-siRNA), a recombinant plasmid, and a corresponding blank control were transfected into PC9/GR cells. Subsequently, Western blot analyses were conducted to assess the expression levels of PRSS8, phosphorylated AKT (p-AKT), AKT, phosphorylated mTOR (p-mTOR), mTOR, and various apoptosis-related proteins within each group. Additionally, a cell proliferation assay utilizing Cell Counting Kit-8 (CCK8) was performed on each group treated with gefitinib.

Results

PRSS8 expression was markedly higher in PC9/GR cells compared to PC9 cells ( 0.05). The group treated with PRSS8-siRNA exhibited significantly reduced protein expression levels of PRSS8, p-AKT, p-mTOR, β-catenin, and BCL-2 compared to the control siRNA (Con-siRNA) group, whereas expressions of Caspase9 and Bax were significantly increased. In the untransfected PC9/GR cells, protein expressions of PRSS8, p-AKT, p-mTOR, and BCL-2 were significantly elevated when compared with the plasmid-transfected group, which also showed a significant reduction in Bax expression. The proliferative activity of the PRSS8-siRNA group post-gefitinib treatment was significantly diminished at 24, 48, and 72 hours in comparison to the Con-siRNA group.

Conclusion

The findings indicate that PRSS8 contributes to the acquisition of resistance to gefitinib in NSCLC, potentially through regulation of the AKT/mTOR signaling pathway.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206296807240717165200
2024-11-01
2024-11-29

  • From This Site

    /content/journals/acamc/10.2174/0118715206296807240717165200
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SungH. FerlayJ. SiegelR.L. LaversanneM. SoerjomataramI. JemalA. BrayF. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.202171320924910.3322/caac.21660 33538338
     [Google Scholar]
  2. ChenP. LiuY. WenY. ZhouC. Non‐small cell lung cancer in China.Cancer Commun.2022421093797010.1002/cac2.12359 36075878
     [Google Scholar]
  3. GuoH. ZhaoL. ZhuJ. ChenP. WangH. JiangM. LiuX. SunH. ZhaoW. ZhengZ. LiW. ChenB. FangQ. YangM. HeY. YangY. Microbes in lung cancer initiation, treatment, and outcome: Boon or bane?Semin. Cancer Biol.202286Pt 21190120610.1016/j.semcancer.2021.05.025 34029741
     [Google Scholar]
  4. XieS. WuZ. QiY. WuB. ZhuX. The metastasizing mechanisms of lung cancer: Recent advances and therapeutic challenges.Biomed. Pharmacother.202113811145010.1016/j.biopha.2021.111450 33690088
     [Google Scholar]
  5. ZhangY. XiongL. XieF. ZhengX. LiY. ZhuL. SunJ. Next‐generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non‐small cell lung cancer.Cancer Med.202110144697470910.1002/cam4.3948 34173341
     [Google Scholar]
  6. ToC. BeyettT.S. JangJ. FengW.W. BahcallM. HaikalaH.M. ShinB.H. HeppnerD.E. RanaJ.K. LeeperB.A. SorokoK.M. PoitrasM.J. GokhaleP.C. KobayashiY. WahidK. KurppaK.J. GeroT.W. CameronM.D. OginoA. MushajiangM. XuC. ZhangY. ScottD.A. EckM.J. GrayN.S. JänneP.A. An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.Nat. Cancer20223440241710.1038/s43018‑022‑00351‑8 35422503
     [Google Scholar]
  7. LuH.L. JieG.L. WuY.L. Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: A review of phase II and III trials.Expert Opin. Emerg. Drugs202227211112610.1080/14728214.2022.2063836 35385682
     [Google Scholar]
  8. RossiA. GalettaD. Systemic therapy for oligoprogression in patients with metastatic NSCLC harboring activating EGFR mutations.Cancers202214383210.3390/cancers14030832 35159099
     [Google Scholar]
  9. ShamseldinH.E. DerarN. AlzaidanH. AlHathalN. AlfalahA. AbdulwahabF. AlzaidT. AlkerayeS. AlobaidaS.A. AlkurayaF.S. PRSS8, encoding prostasin, is mutated in patients with autosomal recessive ichthyosis.Hum. Genet.2023142447748210.1007/s00439‑023‑02527‑3 36715754
     [Google Scholar]
  10. WuL. GongY. YanT. ZhangH. LINP1 promotes the progression of cervical cancer by scaffolding EZH2, LSD1, and DNMT1 to inhibit the expression of KLF2 and PRSS8.Biochem. Cell Biol.202098559159910.1139/bcb‑2019‑0446 32348690
     [Google Scholar]
  11. ChenL.M. ChaiJ.C. LiuB. StruttT.M. McKinstryK.K. ChaiK.X. Prostasin regulates PD-L1 expression in human lung cancer cells.Biosci. Rep.2021417BSR2021137010.1042/BSR20211370 34240739
     [Google Scholar]
  12. JiangL. ZhangJ. XuY. XuH. WangM. Treating non-small cell lung cancer by targeting the PI3K signaling pathway.Chin. Med. J.2022135111272128410.1097/CM9.0000000000002195 35830272
     [Google Scholar]
  13. LiuR. ChenY. LiuG. LiC. SongY. CaoZ. LiW. HuJ. LuC. LiuY. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers.Cell Death Dis.202011979710.1038/s41419‑020‑02998‑6 32973135
     [Google Scholar]
  14. WangS. RongR. YangD.M. FujimotoJ. BishopJ.A. YanS. CaiL. BehrensC. BerryL.D. WilhelmC. AisnerD. ShollL. JohnsonB.E. KwiatkowskiD.J. WistubaI.I. BunnP.A.Jr MinnaJ. XiaoG. KrisM.G. XieY. Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer.J. Clin. Invest.20231332e16033010.1172/JCI160330 36647832
     [Google Scholar]
  15. WangW. XiaX. ChenK. ChenM. MengY. LvD. YangH. Reduced PHLPP expression leads to EGFR-TKI resistance in lung cancer by activating PI3K-AKT and MAPK-ERK dual signaling.Front. Oncol.20211166504510.3389/fonc.2021.665045 34168988
     [Google Scholar]
  16. CaiC. ZhangY. PengX. Knocking down Sterol regulatory element binding protein 2 (SREBF2) inhibits the Serine Protease 8 (PRSS8)/sodium channel epithelial 1alpha subunit (SCNN1A) axis to reduce the cell proliferation, migration and epithelial-mesenchymal transformation of ovarian cancer.Bioengineered20211229390940010.1080/21655979.2021.1978615 34823420
     [Google Scholar]
  17. MiyaiK. YonekuraY. ItoK. MatsukumaS. TsudaH. Gene expression microarray analysis of adult testicular germ cell tumor: A comparison between pure-type seminomas and seminoma components in mixed tumors.Virchows Arch.202147961177118610.1007/s00428‑021‑03168‑5 34347114
     [Google Scholar]
  18. BaoY. GuoY. YangY. WeiX. ZhangS. ZhangY. LiK. YuanM. GuoD. MaciasV. ZhuX. ZhangW. YangW. Correction to: PRSS8 suppresses colorectal carcinogenesis and metastasis.Oncogene202140101922192410.1038/s41388‑021‑01646‑3 33619325
     [Google Scholar]
/content/journals/acamc/10.2174/0118715206296807240717165200
Loading
The Role of Serine Protease 8 in Mediating Gefitinib Resistance in Non-small Cell Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents) 24, 1339 (2024); https://doi.org/10.2174/0118715206296807240717165200
/content/journals/acamc/10.2174/0118715206296807240717165200
/content/journals/acamc/10.2174/0118715206296807240717165200
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): AKT/mTOR signaling pathway; cell proliferation; Gefitinib resistance; non-small cell lung cancer; PC9/GR cells; serine protease 8

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test